

# Sarit Assouline

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6050743/publications.pdf>

Version: 2024-02-01

147  
papers

7,159  
citations

101543

36  
h-index

60623

81  
g-index

147  
all docs

147  
docs citations

147  
times ranked

8884  
citing authors

#	ARTICLE	IF	CITATIONS
1	Venetoclax+Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 1107-1120.	27.0	684
2	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 155-165.	1.6	488
3	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 553-561.	6.3	362
4	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1433-1442.	10.7	306
5	Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. <i>Blood</i> , 2009, 114, 257-260.	1.4	275
6	Safety and activity of the anti-CD79B antibody+drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 704-715.	10.7	272
7	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 481-489.	1.6	265
8	Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. <i>Clinical Cancer Research</i> , 2016, 22, 868-876.	7.0	262
9	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	1.6	257
10	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 612-621.	10.7	214
11	Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. <i>Clinical Cancer Research</i> , 2016, 22, 2290-2300.	7.0	186
12	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , the, 2019, 6, e254-e265.	4.6	184
13	Age and d<sc>PCR</sc> can predict relapse in <sc>CML</sc> patients who discontinued imatinib: The <sc>ISAV</sc> study. <i>American Journal of Hematology</i> , 2015, 90, 910-914.	4.1	181
14	High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome+Negative Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 676-683.	1.6	171
15	The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. <i>Nature</i> , 2014, 511, 90-93.	27.8	168
16	Systemic cancer therapy: achievements and challenges that lie ahead. <i>Frontiers in Pharmacology</i> , 2013, 4, 57.	3.5	165
17	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	1.6	160
18	Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. <i>Blood</i> , 2019, 134, 6-6.	1.4	152

#	ARTICLE	IF	CITATIONS
19	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 4042-4054.	1.6	141
20	Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 695.	7.4	120
21	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 1055-1065.	10.7	119
22	Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 138-149.	4.4	103
23	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. <i>American Journal of Hematology</i> , 2014, 89, 732-742.	4.1	102
24	Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial. <i>American Journal of Hematology</i> , 2017, 92, 1170-1176.	4.1	77
25	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. <i>Blood Advances</i> , 2022, 6, 533-543.	5.2	77
26	Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. <i>Haematologica</i> , 2016, 101, e185-e188.	3.5	68
27	Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 2006, 354, 2623-2624.	27.0	66
28	Phase I/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 164, 258-265.	2.5	65
29	A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. <i>Haematologica</i> , 2015, 100, e7-e9.	3.5	64
30	Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2886-2898.	5.2	59
31	A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). <i>Leukemia and Lymphoma</i> , 2011, 52, 394-399.	1.3	58
32	Oxalic acid excretion after intravenous ascorbic acid administration. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 263-269.	3.4	56
33	Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts). <i>Blood</i> , 2014, 124, 116-116.	1.4	55
34	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. <i>Blood</i> , 2022, 140, 839-850.	1.4	55
35	Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study. <i>Blood</i> , 2018, 132, 399-399.	1.4	48
36	Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. <i>Clinical Chemistry</i> , 2016, 62, 1238-1247.	3.2	45

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. <i>Lancet Haematology</i> , 2016, 3, e128-e138.	4.6	37
38	An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 215-222.	2.5	35
39	Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1001-1009.	2.4	33
40	Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. <i>Haematologica</i> , 2008, 93, 317-318.	3.5	32
41	A review of FDA-approved acute myeloid leukemia therapies beyond $\text{t}^{-7} + 3\text{t}^{\text{TM}}$ . <i>Expert Review of Hematology</i> , 2021, 14, 185-197.	2.2	30
42	Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. <i>Blood</i> , 2019, 134, 229-229.	1.4	30
43	Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). <i>Blood</i> , 2014, 124, 519-519.	1.4	30
44	Monitoring Response and Resistance to Treatment in Chronic Myeloid Leukemia. <i>Current Oncology</i> , 2011, 18, 71-83.	2.2	29
45	Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study. <i>Leukemia Research</i> , 2021, 100, 106489.	0.8	29
46	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020, 25, 878-885.	3.7	28
47	PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 51.	3.0	27
48	Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 4457-4457.	1.4	26
49	Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1585-1585.	1.4	26
50	Treating lymphoma is now a bit EZ-er. <i>Blood Advances</i> , 2021, 5, 2256-2263.	5.2	22
51	Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results. <i>American Journal of Hematology</i> , 2021, 96, 1156-1165.	4.1	22
52	Children Who Can't Smell the Coffee: Isolated Congenital Anosmia. <i>Journal of Child Neurology</i> , 1998, 13, 168-172.	1.4	21
53	Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. <i>Blood</i> , 2018, 132, 767-767.	1.4	21
54	Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received $\geq 2$ Prior Lines of Therapy: Pivotal Results from a Phase I/II Study. <i>Blood</i> , 2021, 138, 127-127.	1.4	20

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. <i>British Journal of Haematology</i> , 2019, 185, 595-598.	2.5	19
56	Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020, 191, 44-51.	2.5	19
57	High-dose vitamin C therapy: Renewed hope or false promise?. <i>Cmaj</i> , 2006, 174, 956-957.	2.0	18
58	Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study. <i>Blood</i> , 2018, 132, 1683-1683.	1.4	18
59	Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. <i>Leukemia and Lymphoma</i> , 2007, 48, 513-520.	1.3	17
60	A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 59-74.	0.4	17
61	Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine. <i>Blood</i> , 2013, 122, 498-498.	1.4	17
62	Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study. <i>Leukemia and Lymphoma</i> , 2014, 55, 533-537.	1.3	16
63	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 355-355.	1.4	16
64	A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 643-651.	2.3	15
65	The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity. <i>ELife</i> , 2017, 6, .	6.0	15
66	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E49-E52.	4.1	14
67	Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study. <i>Blood</i> , 2012, 120, 3822-3822.	1.4	14
68	Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies. <i>Blood</i> , 2013, 122, 1810-1810.	1.4	14
69	Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. <i>Blood</i> , 2017, 130, LBA-2-LBA-2.	1.4	14
70	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. <i>Blood</i> , 2020, 136, 2237-2240.	1.4	13
71	Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma. <i>Blood</i> , 2014, 124, 1701-1701.	1.4	13
72	The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. <i>Blood Advances</i> , 2020, 4, 2011-2017.	5.2	12

#	ARTICLE	IF	CITATIONS
73	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	4.1	12
74	Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia. <i>Blood</i> , 2012, 120, 675-675.	1.4	12
75	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018, 59, 2904-2910.	1.3	11
76	B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. <i>Vaccine</i> , 2022, 40, 1203-1207.	3.8	11
77	Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. <i>Investigational New Drugs</i> , 2020, 38, 1430-1441.	2.6	10
78	Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study. <i>Blood</i> , 2019, 134, 4081-4081.	1.4	10
79	CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell Lymphoma. <i>Translational Oncology</i> , 2021, 14, 101188.	3.7	9
80	The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). <i>Cancers</i> , 2012, 4, 1161-1179.	3.7	8
81	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 184-184.	1.4	8
82	Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months. <i>Blood</i> , 2018, 132, 461-461.	1.4	8
83	Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient. <i>American Journal of Hematology</i> , 2006, 81, 646-646.	4.1	7
84	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. <i>Oncologist</i> , 2020, 25, e993-e997.	3.7	7
85	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018, 132, 1626-1626.	1.4	7
86	Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial. <i>Blood</i> , 2019, 134, 3905-3905.	1.4	7
87	Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study. <i>Blood</i> , 2021, 138, 3573-3573.	1.4	7
88	Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 2011, 52, 1010-1016.	1.3	6
89	Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 627-634.e5.	0.4	6
90	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1653-1659.	1.3	6

#	ARTICLE	IF	CITATIONS
91	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018, 132, 4097-4097.	1.4	5
92	Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab. <i>Blood</i> , 2012, 120, 1637-1637.	1.4	5
93	MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study. <i>Blood</i> , 2012, 120, 3677-3677.	1.4	5
94	Results of a Phase 2 Trial Evaluating Efficacy and Safety of Entospletinib (GS-9973) in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 2963-2963.	1.4	5
95	CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas. <i>Blood</i> , 2019, 134, 1608-1608.	1.4	5
96	Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. <i>Frontiers in Pharmacology</i> , 2013, 4, 9.	3.5	4
97	Rituximab-induced autoimmune hepatitis: A case study and literature review. <i>Canadian Liver Journal</i> , 2020, 3, 381-386.	0.9	4
98	A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 1593-1593.	1.4	4
99	Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update. <i>Blood</i> , 2012, 120, 3785-3785.	1.4	4
100	The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. <i>Blood</i> , 2014, 124, 813-813.	1.4	4
101	Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S380-S381.	0.4	3
102	Subcutaneous rituximab "a meaningful advance in care. <i>Lancet Haematology</i> , the, 2017, 4, e248-e249.	4.6	3
103	A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule 1 (CLL-1) in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E175-E179.	4.1	3
104	An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3) Tj ETQq0 0 0 rgBT /Overlock 1 4728-4728.	1.4	3
105	Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma. <i>Blood</i> , 2012, 120, 3646-3646.	1.4	3
106	A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy. <i>Blood</i> , 2021, 138, 3610-3610.	1.4	3
107	Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia. <i>Journal of Oncology Practice</i> , 2016, 12, 592-594.	2.5	2
108	Risk of infection in MPN patients in the era of COVID-19: A prospective multicenter study of 257 patients from the CMLâ€MPN Q uebec Research Group. <i>American Journal of Hematology</i> , 2021, 96, E200-E203.	4.1	2

#	ARTICLE	IF	CITATIONS
109	Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral. <i>Blood</i> , 2019, 134, 768-768.	1.4	2
110	Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR. <i>Blood</i> , 2019, 134, 29-29.	1.4	2
111	Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP. <i>Blood</i> , 2019, 134, 921-921.	1.4	2
112	Changes in Tumor Immune Micro-Environment in Diffuse Large B-Cell Lymphoma (DLBCL): A Comparative Study of Relapsed Versus Diagnostic DLBCL. <i>Blood</i> , 2019, 134, 3968-3968.	1.4	2
113	TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data. <i>Blood</i> , 2021, 138, 2488-2488.	1.4	2
114	Real-Life Use of Nilotinib for Chronic Phase CML Demonstrates Similar Efficacy and Rate of Cardiovascular Events As Enestnd. <i>Blood</i> , 2021, 138, 4602-4602.	1.4	2
115	Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	2
116	Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?. <i>Leukemia and Lymphoma</i> , 2015, 56, 6-7.	1.3	1
117	Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials. <i>Leukemia and Lymphoma</i> , 2015, 56, 2747-2749.	1.3	1
118	Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 218-221.	1.3	1
119	Improving on R-ICE in relapsed DLBCL. <i>Blood</i> , 2018, 131, 1767-1768.	1.4	1
120	An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 933-942.	2.2	1
121	Chronic myelogenous leukemia presenting as central retinal vein occlusion. <i>Leukemia and Lymphoma</i> , 2020, 61, 2515-2518.	1.3	1
122	Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. <i>Blood</i> , 2018, 132, 453-453.	1.4	1
123	Hepatitis B Virus (HBV) Screening and Associated Outcomes in Malignant Hematology Patients Receiving Rituximab Therapy within the Rossy Cancer Network. <i>Blood</i> , 2018, 132, 2256-2256.	1.4	1
124	Prediction of High-Risk Group of Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using a CT-Based Radiomics Model with Machine Learning. <i>Blood</i> , 2019, 134, 4136-4136.	1.4	1
125	MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study. <i>Blood</i> , 2011, 118, 2672-2672.	1.4	1
126	Engage: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Study To Investigate The Efficacy and Safety Of Eliglustat In Adults With Gaucher Disease Type 1: 9 Month Results. <i>Blood</i> , 2013, 122, 2275-2275.	1.4	1



#	ARTICLE	IF	CITATIONS
127	FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance. Blood, 2014, 124, 3018-3018.	1.4	1
128	Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. Blood, 2016, 128, 4194-4194.	1.4	1
129	Impact Of Dedicated CML Clinic On The Outcome Of Patients With Newly Diagnosed CML: Experience Of a Single Canadian Center. Blood, 2013, 122, 5186-5186.	1.4	1
130	Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood, 2014, 124, 4472-4472.	1.4	1
131	Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. Blood, 2021, 138, 1476-1476.	1.4	1
132	Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments. Critical Reviews in Oncology/Hematology, 2022, , 103711.	4.4	1
133	IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S406-S407.	0.4	0
134	Higher Prevalence of Prior Prostate Cancer in Patients Diagnosed with Chronic Myelogenous Leukemia.. Blood, 2006, 108, 4795-4795.	1.4	0
135	Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,. Blood, 2011, 118, 3766-3766.	1.4	0
136	A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E,. Blood, 2011, 118, 3606-3606.	1.4	0
137	A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase. Blood, 2011, 118, 4437-4437.	1.4	0
138	Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients. Blood, 2013, 122, 4040-4040.	1.4	0
139	Accrual Of Patients With Relapsed and Refractory DLBCL Onto Clinical Trials. Blood, 2013, 122, 3041-3041.	1.4	0
140	A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1. Blood, 2013, 122, 821-821.	1.4	0
141	Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BQ25341). Blood, 2014, 124, 1995-1995.	1.4	0
142	Engage - a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Eliglustat in Adults with Gaucher Disease Type 1: Results after 18 Months. Blood, 2014, 124, 2732-2732.	1.4	0
143	A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 2719-2719.	1.4	0
144	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. Blood, 2018, 132, 93-93.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Improving End of Life Care for Hematology-Oncology Patients within the Rossy Cancer Network. Blood, 2019, 134, 4775-4775.	1.4	0
146	Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg. Blood, 2019, 134, 1766-1766.	1.4	0
147	Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG. Blood, 2021, 138, 220-220.	1.4	0